ClearPoint Neuro (CLPT) to Release Quarterly Earnings on Tuesday

ClearPoint Neuro (NASDAQ:CLPT) is expected to be issuing its quarterly earnings data after the market closes on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $8.23 million for the quarter. ClearPoint Neuro has set its FY 2025 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The business had revenue of $7.77 million for the quarter, compared to the consensus estimate of $8.23 million. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Stock Down 0.9 %

Shares of CLPT opened at $13.07 on Friday. The stock has a market capitalization of $361.15 million, a P/E ratio of -18.94 and a beta of 1.06. ClearPoint Neuro has a twelve month low of $5.11 and a twelve month high of $19.22. The company has a 50 day moving average of $16.42 and a 200-day moving average of $13.96.

Analyst Ratings Changes

Several research firms have recently commented on CLPT. Lake Street Capital increased their price objective on ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, January 21st. B. Riley increased their price objective on ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, January 28th.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.